Last updated on December 2018

Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: alpha-1-Antitrypsin deficiency
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Key Inclusion Criteria:

  • Capable of providing informed consent
  • Alpha1AT genotype of ZZ or Z Null
  • Males and females 18 years and older
  • Ongoing treatment with A1AT augmentation is not required, however any subject receiving A1AT augmentation therapy must be willing to washout. Washout is defined as at least 8 weeks between last augmentation therapy and pre-treatment plasma A1AT level
  • Willing to remain off PAT for at least 3 months following treatment
  • Body mass index 18 to 35 kg/m2
  • Fertile men and women of childbearing potential must agree to use barrier contraception for 3 months after treatment

Key Exclusion Criteria:

  • FEV1 <35 percent of predicted value at the Screening visit
  • Receiving systemic corticosteroids or other immunosuppressive medications
  • Immunodeficiency disease or evidence of active infection of any type, including human immunodeficiency virus
  • Abnormal liver function tests
  • Organ transplant recipient or awaiting transplantation
  • Participation in another current or previous gene transfer study
  • AAVrh.10 neutralizing antibody titer 1:5
  • Female who is pregnant or lactating
  • History of alcohol or drug abuse within the past 5 years
  • Any history of allergies that may prohibit study-specific investigations
  • Receiving an investigational medicinal product or participating in another investigational study within 3 months prior to consent
  • Cigarette smoking, or any other tobacco use, e-cigarettes or other recreational inhalant within 1 year of the Screening Visit

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.